Impaired ganglioside metabolism in Huntington's disease and neuroprotective role of GM1

Journal of Neuroscience

Volumn 30, Issue 11, 2010, Pages 4072-4080

  Maglione, Vittorio ^a   Marchi, Paolo ^a   Di Pardo, Alba ^a   Lingrell, Susanne ^a   Horkey, Melanie ^a   Tidmarsh, Emily ^a   Sipione, Simonetta ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GM1; HUNTINGTIN; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; BRAIN; CELL LINE, TRANSFORMED; CELLS, CULTURED; FEMALE; FIBROBLASTS; G(M1) GANGLIOSIDE; GENE KNOCK-IN TECHNIQUES; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; PEPTIDES; RATS;

EID: 77949735761     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.6348-09.2010     Document Type: Article

References (51)

1. Abad-Rodriguez J, Robotti A (2007) Regulation of axonal development by plasma membrane gangliosides. J Neurochem 103 [Suppl 1]: 47-55.
2. Alter M (1998) GM1 ganglioside for acute ischemic stroke. Trial design issues. Ann N Y Acad Sci 845:391- 401.
3. Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y, Hayward SD, Moran TH, Montell C, Ross CA, Snyder SH, Sawa A (2005) p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47:29-41.
4. Chiavegatto S, Sun J, Nelson RJ, Schnaar RL (2000) A functional role for complex gangliosides: motor deficits in GM2/GD2 synthase knockout mice. Exp Neurol 166:227-234.
5. Chinnock P, Roberts I (2005) Gangliosides for acute spinal cord injury. Cochrane Database Syst Rev 2:CD004444.
6. Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, Squitieri F (2006) Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med 47:215-222.
7. Clarke G, Collins RA, Leavitt BR, Andrews DF, Hayden MR, Lumsden CJ, McInnes RR (2000) A one-hit model of cell death in inherited neuronal degenerations. Nature 406:195-199.
8. Colin E, Régulier E, Perrin V, Dürr A, Brice A, Aebischer P, Déglon N, Humbert S, Saudou F (2005) Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci 21:1478 -1488.
9. Cornett J, Smith L, Friedman M, Shin JY, Li XJ, Li SH (2006) Context-dependent dysregulation of transcription by mutant huntingtin. J Biol Chem 281:36198 -36204.
10. Da Silva JS, Hasegawa T, Miyagi T, Dotti CG, Abad-Rodriguez J (2005) Asymmetric membrane ganglioside sialidase activity specifies axonal fate. Nat Neurosci 8:606-615.
11. Desplats PA, Denny CA, Kass KE, Gilmartin T, Head SR, Sutcliffe JG, Seyfried TN, Thomas EA (2007) Glycolipid and ganglioside metabolism imbalances in Huntington's disease. Neurobiol Dis 27:265-277.
12. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, Mouradian MM, Young AB, Tanese N, Krainc D (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296:2238 -2243.
13. Ferrari G, Anderson BL, Stephens RM, Kaplan DR, Greene LA (1995) Prevention of apoptotic neuronal death by GM1 ganglioside. Involvement of Trk neurotrophin receptors. J Biol Chem 270:3074 -3080.
14. Furuse H, Waki H, Kaneko K, Fujii S, Miura M, Sasaki H, Ito KI, Kato H, Ando S (1998) Effect of the mono- and tetra-sialogangliosides, GM1 and GQ1b, on long-term potentiation in the CA1 hippocampal neurons of the guinea pig. Exp Brain Res 123:307-314.
15. Hakomori Si SI (2002) Inaugural article: the glycosynapse. Proc Natl Acad Sci U S A 99:225-232.
16. Holmgren J, Lönnroth I, Månsson J, Svennerholm L (1975) Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc Natl Acad Sci U S A 72:2520 -2524.
17. Humbert S, Bryson EA, Cordelières FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2:831- 837.
18. Ichikawa N, Iwabuchi K, Kurihara H, Ishii K, Kobayashi T, Sasaki T, Hattori N, Mizuno Y, Hozumi K, Yamada Y, Arikawa-Hirasawa E (2009) Binding of laminin-1 to monosialoganglioside GM1 in lipid rafts is crucial for neurite outgrowth. J Cell Sci 122:289 -299.
19. Imarisio S, Carmichael J, Korolchuk V, Chen CW, Saiki S, Rose C, Krishna G, Davies JE, Ttofi E, Underwood BR, Rubinsztein DC (2008) Huntington's disease: from pathology and genetics to potential therapies. Biochem J 412:191-209.
20. Kaplan DR, Miller FD (2000) Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10:381-391.
21. Karten B, Hayashi H, Francis GA, Campenot RB, Vance DE, Vance JE (2005) Generation and function of astroglial lipoproteins from Niemann-Pick type C1-deficient mice. Biochem J 387:779 -788.
22. Ladisch S, Gillard B (1985) A solvent partition method for microscale ganglioside purification. Anal Biochem 146:220 -231.
23. Ledeen RW, Wu G (2008) Nuclear sphingolipids: metabolism and signaling. J Lipid Res 49:1176 -1186.
24. Luo S, Vacher C, Davies JE, Rubinsztein DC (2005) Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J Cell Biol 169:647- 656.
25. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506.
26. Mocchetti I (2005) Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell Mol Life Sci 62:2283-2294.
27. Oppenheimer S (1990) GM1 ganglioside therapy in acute ischemic stroke. Stroke 21:825.
28. Pope-Coleman A, Tinker JP, Schneider JS (2000) Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys. Synapse 36:120 -128.
29. Prinetti A, Loberto N, Chigorno V, Sonnino S (2009) Glycosphingolipid behaviour in complex membranes. Biochim Biophys Acta 1788:184 -193.
30. Qiu Z, Norflus F, Singh B, Swindell MK, Buzescu R, Bejarano M, Chopra R, Zucker B, Benn CL, DiRocco DP, Cha JH, Ferrante RJ, Hersch SM (2006) Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J Biol Chem 281:16672-16680.
31. Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, Clementi E, Hackam A, Hayden MR, Li Y, Cooper JK, Ross CA, Govoni S, Vincenz C, Cattaneo E (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 20:3705-3713.
32. Schilling B, Gafni J, Torcassi C, Cong X, Row RH, LaFevre-Bernt MA, Cusack MP, Ratovitski T, Hirschhorn R, Ross CA, Gibson BW, Ellerby LM (2006) Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity. J Biol Chem 281:23686 -23697.
33. Schneider JS (1998) GM1 ganglioside in the treatment of Parkinson's disease. Ann N Y Acad Sci 845:363-373.
34. Sheikh KA, Sun J, Liu Y, Kawai H, Crawford TO, Proia RL, Griffin JW, Schnaar RL (1999) Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc Natl Acad Sci U S A 96:7532-7537.
35. Simpson MA, Cross H, Proukakis C, Priestman DA, Neville DC, Reinkensmeier G, Wang H, Wiznitzer M, Gurtz K, Verganelaki A, Pryde A, Patton MA, Dwek RA, Butters TD, Platt FM, Crosby AH (2004) Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat Genet 36:1225-1229.
36. Singhrao SK, Thomas P, Wood JD, MacMillan JC, Neal JW, Harper PS, Jones AL (1998) Huntingtin protein colocalizes with lesions of neurodegenerative diseases: an investigation in Huntington's, Alzheimer's, and Pick's diseases. Exp Neurol 150:213-222.
37. Sipione S, Rigamonti D, Valenza M, Zuccato C, Conti L, Pritchard J, Kooperberg C, Olson JM, Cattaneo E (2002) Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet 11:1953-1965.
38. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, HaydenMR (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12: 1555-1567.
39. Song C, Perides G, Liu YF (2002) Expression of full-length polyglutamine-expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells. J Biol Chem 277:6703- 6707.
40. Sonnino S, Mauri L, Chigorno V, Prinetti A (2007) Gangliosides as components of lipid membrane domains. Glycobiology 17:1R-13R.
41. Squitieri F, Frati L, Ciarmiello A, Lastoria S, Quarrell O (2006) Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease? Mech Ageing Dev 127:208 -212.
42. Tettamanti G (2004) Ganglioside/glycosphingolipid turnover: new concepts. Glycoconj J 20:301-317.
43. Tettamanti G, Morgan IG, Gombos G, Vincendon G, Mandel P (1972) Subsynaptosomal localization of brain particulate neuraminidose. Brain Res 47:515-518.
44. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, Cattaneo E, MacDonald ME (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 9:2799 -2809.
45. Wade A, Jacobs P, Morton AJ (2008) Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation. Brain Res 1188:61- 68.
46. Walker FO (2007) Huntington's disease. Lancet 369:218 -228.
47. Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, Hayden MR (2009) Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci 40:121-127.
48. Wu G, Lu ZH, Xie X, LedeenRW (2004) Susceptibility of cerebellar granule neurons from GM2/GD2 synthase-null mice to apoptosis induced by glutamate excitotoxicity and elevated KCl: rescue by GM1 and LIGA20. Glycoconj J 21:305-313.
49. Wu G, Lu ZH, Wang J, Wang Y, Xie X, Meyenhofer MF, Ledeen RW (2005) Enhanced susceptibility to kainate-induced seizures, neuronal apoptosis, and death in mice lacking gangliotetraose gangliosides: protection with LIGA 20, a membrane-permeant analog of GM1. J Neurosci 25:11014 -11022.
50. Yu RK, Bieberich E, Xia T, Zeng G (2004) Regulation of ganglioside biosynthesis in the nervous system. J Lipid Res 45:783-793.
51. Zala D, Colin E, Rangone H, Liot G, Humbert S, Saudou F (2008) Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 17:3837-3846.